170 related articles for article (PubMed ID: 36220762)
1. Radical Transurethral Resection of Bladder Tumor in Seemingly Organ-confined Muscle-invasive Bladder Cancer: Con.
Maas M; Black PC
Eur Urol Focus; 2023 Mar; 9(2):223-224. PubMed ID: 36220762
[TBL] [Abstract][Full Text] [Related]
2. Radical Transurethral Resection of Bladder Tumor in Organ-confined Muscle-invasive Bladder Cancer: Yes!
Wood EL; Djaladat H
Eur Urol Focus; 2023 Mar; 9(2):225-226. PubMed ID: 36344396
[TBL] [Abstract][Full Text] [Related]
3. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder.
Supit W; Mochtar CA; Santoso RB; Umbas R
Asian J Surg; 2014 Oct; 37(4):184-9. PubMed ID: 24637186
[TBL] [Abstract][Full Text] [Related]
5. Timing and outcomes for radical cystectomy in nonmuscle invasive bladder cancer.
Zehnder P; Thalmann GN
Curr Opin Urol; 2013 Sep; 23(5):423-8. PubMed ID: 23880740
[TBL] [Abstract][Full Text] [Related]
6. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
7. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP; Bilen MA; Jani AB
Am J Clin Oncol; 2019 Jan; 42(1):36-41. PubMed ID: 29912804
[TBL] [Abstract][Full Text] [Related]
9. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer.
Ballas L; Singh P; Lerner SP
Urol Oncol; 2023 Jan; 41(1):35-38. PubMed ID: 33153882
[TBL] [Abstract][Full Text] [Related]
10. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study.
Fujiwara M; Yokoyama M; Toide M; Fujiwara R; Tanaka H; Oguchi T; Komai Y; Yoshida S; Matsuoka Y; Numao N; Yamamoto S; Fukui I; Yonese J; Fujii Y
Jpn J Clin Oncol; 2023 Mar; 53(3):263-269. PubMed ID: 36524369
[TBL] [Abstract][Full Text] [Related]
11. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?
Kaimakliotis HZ; Monn MF; Cary KC; Pedrosa JA; Rice K; Masterson TA; Gardner TA; Hahn NM; Foster RS; Bihrle R; Cheng L; Koch MO
Urol Oncol; 2014 Aug; 32(6):833-8. PubMed ID: 24954925
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study.
Zheng Y; Ye Y; Chen J; Wei Z; Liu Z; Yu K; Zhang X
Int J Surg; 2022 Jul; 103():106693. PubMed ID: 35690361
[TBL] [Abstract][Full Text] [Related]
13. [Radical cystectomy in the treatment of bladder cancer always in due time?].
May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study.
Kobayashi K; Matsumoto H; Misumi T; Ito H; Hirata H; Nagao K; Matsuyama H
Jpn J Clin Oncol; 2022 Oct; 52(10):1201-1207. PubMed ID: 35675636
[TBL] [Abstract][Full Text] [Related]
15. Optimal timing of radical cystectomy for patients with T1 bladder cancer.
Bochner BH
Urol Oncol; 2009; 27(3):329-31. PubMed ID: 19414124
[TBL] [Abstract][Full Text] [Related]
16. Preoperative detection of Vesical Imaging-Reporting and Data System (VI-RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?
Del Giudice F; Leonardo C; Simone G; Pecoraro M; De Berardinis E; Cipollari S; Flammia S; Bicchetti M; Busetto GM; Chung BI; Gallucci M; Catalano C; Panebianco V
BJU Int; 2020 Nov; 126(5):610-619. PubMed ID: 32783347
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer.
Kanady KE; Shipley WU; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Semin Surg Oncol; 1997; 13(5):359-64. PubMed ID: 9259092
[TBL] [Abstract][Full Text] [Related]
18. The current status of bladder preservation in the treatment of muscle invasive bladder cancer.
Kim HL; Steinberg GD
J Urol; 2000 Sep; 164(3 Pt 1):627-32. PubMed ID: 10953112
[TBL] [Abstract][Full Text] [Related]
19. Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection.
Han B; Liang S; Jing Y; Cui D; An X; Zou Q; Wei H; Xia S
Med Oncol; 2014 Apr; 31(4):912. PubMed ID: 24627238
[TBL] [Abstract][Full Text] [Related]
20. Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.
Ericson KJ; Murthy PB; Bryk DJ; Ramkumar RR; Broughman JR; Khanna A; Mian OY; Campbell SC
Clin Adv Hematol Oncol; 2019 Dec; 17(12):697-707. PubMed ID: 31851158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
